The pharmaceutical industry is continuously evolving, with substantial demand for high-quality Active Pharmaceutical Ingredients (APIs). Dulaglutide, a GLP-1 receptor agonist, represents copyrightple of this trend. To address this demand, US-based manufacturing services are gaining traction. These pro